In a phase 1b clinical trial in Chinese overweight adults or adults with obesity, mazdutide dosed up 10 mg was well tolerated, with overall safety profiles similar to those of other GLP-1 receptor agonists and co-agonists12,13. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.